2022 World Conference on Lung Cancer (ePosters)-EP08.02-068. ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)

EP08.02-068. ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)

Back to course

Pdf Summary

In this document, the authors discuss the differences in ALK-dependent resistance mechanisms to the ALK TKI ensartinib between the ALK fusion subtypes Variant 1 (V1) and Variant 3 (V3). They conducted a phase II clinical trial and analyzed plasma samples from non-small cell lung cancer patients after crizotinib treatment. They found that the most common ALK mutation at baseline was L1196M in V1 subtype and both L1196M and C1156Y in V3 subtype. After resistance to ensartinib, the V1 subtype mainly developed the G1269A mutation, while the V3 subtype mainly developed the G1202R mutation. The frequencies of the E1210K mutation were similar in both groups. The authors concluded that the incidence of ensartinib-associated ALK resistance mutations differs between the V1 and V3 subtypes. This difference could potentially guide the selection of later-line therapy in these patients.

Asset Subtitle

Jie Huang

Meta Tag

Speaker Jie Huang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ALK-dependent resistance mechanisms

ALK TKI ensartinib

ALK fusion subtypes

Variant 1

Variant 3

L1196M

C1156Y

G1269A mutation

G1202R mutation

E1210K mutation